Point of Care Diagnostics Market Size is projected to reach USD 66.37 billion by 2030, growing at a CAGR of 6.67%: Straits Research
The global point of care diagnostics market size was valued at USD 37.12 billion in 2021. It is projected to reach USD 66.37 billion by 2030, growing at a CAGR of 6.67% during the forecast period (2022–2030), The residential end-use market sector is anticipated to grow at a CAGR of 7.5% during the forecast period.
New York, United States, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Point-of-Care diagnostics are techniques used for the early and rapid diagnosis of disease. These techniques are susceptible and cost-effective and are applied in hospitals, clinics, ambulatory care, home healthcare, and research laboratories. The increasing prevalence of target illnesses is the most important factor driving market expansion. Point of care treatment permits speedy and dependable diagnostic testing with instantaneous results, enabling physicians/patients to make care-related decisions remotely and immediately.
*
*
*Get a Free Sample Copy of This Report @ **https://straitsresearch.com/report/point-of-care-diagnostics-market/request-sample*
*
*
*Increasing Value of Point of Care Diagnostics for Environmental Monitoring and Public Health and Proliferation of Infectious Diseases Drives the Global Market*
The growing significance of point-of-care diagnostics in environmental monitoring and public health necessitates the development of technologies that simplify networking, making it more comfortable for medical practitioners to interpret test findings appropriately. Point-of-care tests can significantly improve the management of infectious diseases, especially in developing countries where timely access to healthcare can be challenging and when the healthcare system is underdeveloped and underfunded. In East and Southern Africa in 2021, UNAIDS estimated approximately 21.2 million HIV-positive individuals. Twenty thousand newly diagnosed cases of HIV were tallied throughout the Middle East and North Africa. It is anticipated that the demand for diagnostics that can be completed at the point of care will rise, accelerating the process of treating HIV infection.
*Evolution of Remote Monitoring of Patients Creates Tremendous Opportunities*
The application of digital technology is projected to substantially impact the creation of POC solutions in settings with limited resources. As part of their go-to-market strategy, businesses in the POCT sector should place the utmost importance on expanding their use of telehealth as the industry standard. It is anticipated that the emergence of remote patient monitoring systems such as PixCell Medical, point-of-care technology for CBC testing, would benefit the market's development.
*
*
*Report Scope*
*Report Metric* *Details*
*Market Size by 2030* USD 66.37 billion
*Market Size in 2021* USD 37.12 billion
*CAGR* 6.67% (2022-2030)
*Historical Data* 2019-2020
*Base Year* 2021
*Forecast Period* 2022-2030
*Forecast Units* Value (USD Billion)
*Report Coverage* Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
*Segments Covered* Product, End-User
*Geographies Covered* North America, Europe, Asia-Pacific, LAME and Rest of the World
*Key Companies Profiled/Vendors* F. Hoffmann-La Roche Ltd.; Qiagen; Danaher Corp.; Becton Dickinson (BD); Biomerieux SA; Abbott Laboratories; Siemens Healthcare AG; Zoetis, Inc.; Instrumentation Laboratory; Nova Biomedical; Trividia Health, Inc.; Quidel Corp.; Trinity Biotech; Sekisui Diagnostics; Orasure Technologies, Inc.; Nipro Corp.; Spectral Medical, Inc.
*Key Market Opportunities* Implementation of Remote Patient Monitoring
*Key Market Drivers* Growing Significance in Environmental Monitoring and Public Health
Rise of Infectious Diseases
*Buy Now Full Report @ **https://straitsresearch.com/buy-now/point-of-care-diagnostics-market *
*
*
*Regional Analysis*
North America maintained the largest revenue share in the global point of care diagnostics market due to the rapidly increasing number of COVID-19 cases and critical players in both the United States and Canada. For example, in March 2022, the company bioLytical Laboratories Inc., situated in Canada, was awarded CE marking for the iStatis COVID-19 Antigen Home Test.
*Key Highlights*
· The global point of care diagnostics market size was valued at *USD 37.12 billion in 2021*. It is projected to reach *USD 66.37 billion by 2030*, growing at a *CAGR of 6.67%* during the forecast period (2022–2030).
· *Based on product, *the market is divided into Glucose Testing, Hb1Ac Testing, Coagulation Testing, Fertility/Pregnancy, Infectious Disease, Cardiac Markers, Thyroid Stimulating Hormone, Hematology, Primary Care Systems, Decentralized Clinical Chemistry, Feces, Lipid Testing, Cancer Marker, Blood Gas/Electrolytes, Ambulatory Chemistry, Drug of Abuse (DOA) Testing, and Urinalysis/Nephrology. The infectious disorders segment owns a significant market share and is expected to grow during the forecast period.
· *Based on end-user, *the market is segmented into clinics, hospitals, homes, assisted living healthcare facilities, and laboratories. The clinic segment is the most dominant in the global point of care diagnostics market, and pharmacy and retail clinics as the most significant contributors to this segment revenue.
· *North America *maintained the largest revenue share in the global point of care diagnostics market.
*Competitors in Point of Care Diagnostics Market*
· F. Hoffmann-La Roche Ltd
· Qiagen
· Danaher Corp.
· Becton Dickinson (BD)
· Biomerieux SA
· Abbott Laboratories
· Siemens Healthcare AG
· Zoetis, Inc
· Instrumentation Laboratory
· Nova Biomedical
· Trividia Health, Inc
· Quidel Corp
· Trinity Biotech
· Sekisui Diagnostics
· Orasure Technologies, Inc
· Nipro Corp.
· Spectral Medical, Inc
*
*
*Get a Free Sample Copy of This Report @ **https://straitsresearch.com/report/point-of-care-diagnostics-market/request-sample** *
*
*
*Segmentation of Point of Care Diagnostics Market*
*By Product*
· Glucose Testing
· Hb1Ac Testing
· Coagulation Testing
· Fertility/Pregnancy
· Infectious Disease
· Cardiac Markers
· Thyroid Stimulating Hormone
· Hematology
· Primary Care Systems
· Decentralized Clinical Chemistry
· Feces
· Lipid Testing
· Cancer Marker
· Blood Gas/Electrolytes
· Ambulatory Chemistry
· Drug of Abuse (DOA) Testing
· Urinalysis/Nephrology
*By End-User*
· Clinics
· Hospitals
· Home
· Assisted Living Healthcare Facilities
· Laboratories
*By Regions*
· North America
· Europe
· Asia-Pacific
· LAMEA
*TABLE OF CONTENT*
1. *EXECUTIVE SUMMARY*
2. *RESEARCH SCOPE & SEGMENTATION*
1. RESEARCH OBJECTIVES
2. MARKET DEFINITION
3. LIMITATIONS & ASSUMPTIONS
4. MARKET SCOPE & SEGMENTATION
5. CURRENCY & PRICING CONSIDERED
3. *MARKET OPPORTUNITY ASSESSMENT*
1. EMERGING REGIONS / COUNTRIES
2. EMERGING COMPANIES
3. EMERGING APPLICATIONS / END USE
4. INVESTMENT LANDSCAPE
5. NEW BUSINESS MODELS / REVENUE STREAMS
6. TAM
4. *MARKET TRENDS*
1. DRIVERS
2. MARKET WARNING FACTORS
3. LATEST MACRO ECONOMIC INDICATORS
4. GEOPOLITICAL IMPACT
5. HUMAN FACTORS
6. TECHNOLOGY FACTORS
5. *MARKET ASSESSMENT*
1. PORTERS FIVE FORCES ANALYSIS
2. VALUE CHAIN ANALYSIS
3. SALES AND DISTRIBUTION CHANNEL ANALYSIS
4. TRADE ANALYSIS
5. AVERAGE PRICING ANALYSIS
6. PATENT ANALYSIS
7. M & A AGREEMENTS & COLLABRATION ANALYSIS
8. COST STRUCTURE ANALYSIS
6. *ESG TRENDS*
7. *GLOBAL POINT OF CARE DIAGNOSTICS MARKET SIZE ANALYSIS*
1. GLOBAL POINT OF CARE DIAGNOSTICS MARKET INTRODUCTION
2. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
3. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
8. *NORTH AMERICA MARKET ANALYSIS*
1. INTRODUCTION
2. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
3. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
4. *U.S.*
1. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
2. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
5. *CANADA*
9. *EUROPE MARKET ANALYSIS*
1. INTRODUCTION
2. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
3. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
4. *U.K.*
1. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
2. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
5. *GERMANY*
6. *FRANCE*
7. *SPAIN*
8. *ITALY*
9. *RUSSIA*
10. *NORDIC*
11. *BENELUX*
12. *REST OF EUROPE*
10. *APAC MARKET ANALYSIS*
1. INTRODUCTION
2. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
3. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
4. *CHINA*
1. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
2. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
5. *KOREA*
6. *JAPAN*
7. *INDIA*
8. *AUSTRALIA*
9. *TAIWAN*
10. *SOUTH EAST ASIA*
11. *REST OF ASIA-PACIFIC*
11. *MIDDLE EAST AND AFRICA MARKET ANALYSIS*
1. INTRODUCTION
2. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
3. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
4. *UAE*
1. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
2. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
5. *TURKEY*
6. *SAUDI ARABIA*
7. *SOUTH AFRICA*
8. *EGYPT*
9. *NIGERIA*
10. *REST OF MEA*
12. *LATAM MARKET ANALYSIS*
1. INTRODUCTION
2. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
3. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
4. *BRAZIL*
1. BY PRODUCT
1. INTRODUCTION
1. PRODUCT BY VALUE
2. GLUCOSE TESTING
1. BY VALUE
3. HB1AC TESTING
1. BY VALUE
4. COAGULATION TESTING
1. BY VALUE
5. FERTILITY/PREGNANCY
1. BY VALUE
6. INFECTIOUS DISEASE
1. BY VALUE
7. CARDIAC MARKERS
1. BY VALUE
8. THYROID STIMULATING HORMONE
1. BY VALUE
9. HEMATOLOGY
1. BY VALUE
10. PRIMARY CARE SYSTEMS
1. BY VALUE
11. DECENTRALIZED CLINICAL CHEMISTRY
1. BY VALUE
12. FECES
1. BY VALUE
13. LIPID TESTING
1. BY VALUE
14. CANCER MARKER
1. BY VALUE
15. BLOOD GAS/ELECTROLYTES
1. BY VALUE
16. AMBULATORY CHEMISTRY
1. BY VALUE
17. DRUG OF ABUSE (DOA) TESTING
1. BY VALUE
18. URINALYSIS/NEPHROLOGY
1. BY VALUE
2. BY END-USER
1. INTRODUCTION
1. END-USER BY VALUE
2. CLINICS
1. BY VALUE
3. HOSPITALS
1. BY VALUE
4. HOME
1. BY VALUE
5. ASSISTED LIVING HEALTHCARE FACILITIES
1. BY VALUE
6. LABORATORIES
1. BY VALUE
5. *MEXICO*
6. *ARGENTINA*
7. *CHILE*
8. *COLOMBIA*
9. *REST OF LATAM*
13. *COMPETITIVE ASSESSMENT*
1. ADOPTION MATRIX
2. POINT OF CARE DIAGNOSTICS MARKET SHARE BY MANUFACTURERS
3. POINT OF CARE DIAGNOSTICS MARKET RANKING BY REVENUE FOR MANUFACTURERS
4. AVERAGE PRICE BY MANUFACTURERS
5. VENDOR FOOTPRINT ANALYSIS
14. *MARKET PLAYERS ASSESSMENT*
1. *HOFFMANN-LA ROCHE LTD.*
1. OVERVIEW
2. BUSINESS INFORMATION
3. REVENUE
4. ASP
5. GROSS MARGIN
6. SWOT ANALYSIS
7. RECENT DEVELOPMMENTS
2. QIAGEN
3. DANAHER CORP.
4. BECTON DICKINSON (BD)
5. BIOMERIEUX SA
6. ABBOTT LABORATORIES
7. SIEMENS HEALTHCARE AG
8. ZOETIS INC.
9. INSTRUMENTATION LABORATORY
10. NOVA BIOMEDICAL
11. TRIVIDIA HEALTH INC.
12. QUIDEL CORP.
13. TRINITY BIOTECH
14. SEKISUI DIAGNOSTICS
15. ORASURE TECHNOLOGIES INC.
16. NIPRO CORP.
17. SPECTRAL MEDICAL INC
15. *RESEARCH METHODOLOGY*
1. RESEARCH DATA
1. SECONDARY DATA
1. MAJOR SECONDARY SOURCES
2. KEY DATA FROM SECONDARY SOURCES
2. PRIMARY DATA
1. KEY DATA FROM PRIMARY SOURCES
2. BREAKDOWN OF PRIMARIES
3. SECONDARY AND PRIMARY RESEARCH
1. KEY INDUSTRY INSIGHTS
2. MARKET SIZE ESTIMATION
1. BOTTOM-UP APPROACH
2. TOP-DOWN APPROACH
3. MARKET PROJECTION
3. RESEARCH ASSUMPTIONS
1. ASSUMPTIONS
4. LIMITATIONS
5. RISK ASSESSMENT
16. *APPENDIX*
1. DISCUSSION GUIDE
2. CUSTOMIZATION OPTIONS
3. RELATED REPORTS
17. *DISCLAIMER*
*
*
*Table of Content and Figure @ **https://straitsresearch.com/report/point-of-care-diagnostics-market/toc *
*
*
*Recent Development*
· *June 2022- *Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics.
· *June 2022-* Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options.
· *May 2022-* QIAGEN launches therascreen EGFR Plus RGQ PCR Kit featuring C797S detection to help guide non-small cell lung cancer (NSCLC) treatment.
· *June 2022-* BD Collaborates with Mayo Clinic Platform, Leveraging Real-World Clinical Data to Improve Post-Market Device Surveillance, Drive Innovation for Patient Care.
*
*
*News Media*
*Global Veterinary Point of Care Diagnostics Market to Grow at a CAGR of 10.45% During 2020 –2030*
*Global Point of Care Diagnostics Market Grows Steadily at a CAGR of 6.67%*
*
*
*Have a Look at the Related Research Report*
*Veterinary Point of Care Diagnostics Market*: Information by Animal Type (Companion, Livestock), Product (Consumables, Reagents), Sample Type (Urine, Fecal), and Regions—Forecast Till 2030
*Ambulatory Surgery Center Market*: Information by Products & Services (Clinical It Solutions, Non-Clinical Healthcare It Solutions), Components (Services), and Region — Forecast till 2030
*Smart Home Healthcare Market*: Information by Aging-in-Place (Perspective of Aging in Smart Homes), General Health and Wellness (Concept of General Health), and Region—Forecast Till 2031
*Home Healthcare Devices Market*: Information By Product (BP & Heart Rate Monitor, Ovulation Kit, Pedometer, Cane, wheelchair), Software, Services, and Regional Outlook - Forecast Till 2030
*Veterinary Infectious Disease Diagnostics Market*: Information by Product (Immunodiagnostics, Molecular Diagnostics), Application (Dogs, Cats), and Regions—Forecast Till 2031
*
*
*About Straits Research Pvt. Ltd.*
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.
Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.
For more information on your target market, please contact us below:
*Phone:* +1 646 480 7505 (the U.S.)
+91 8087085354 (APAC)
+44 208 068 9665 (the U.K.)
*Email: sales@straitsresearch.com*
* Follow Us: LinkedIn | Facebook | Instagram | Twitter *